Filing identity and reporting period
Important metadata mismatch: The request identifies Vyome Holdings, Inc., but the supplied Form 10-Q is for Obalon Therapeutics, Inc. This summary covers Obalon’s unaudited third quarter and nine months ended September 30, 2016; balance-sheet comparisons are with December 31, 2015. Dollar amounts below are in millions unless noted.
Business context and financial results
Obalon is a commercial-stage medical-device company developing and selling its swallowable intragastric balloon system. The FDA approved the current system in September 2016 for temporary weight-loss use in eligible adults. Before its planned U.S. launch, early 2017, sales were international and concentrated in one related-party distributor.
- Revenue: Q3 2016 revenue was $0.77 million, down from $1.09 million in Q3 2015. Nine-month revenue was $2.62 million, down from $3.06 million. All nine-month 2016 revenue came from related-party distributor Bader Sultan & Bros.
- Gross profit and margin: Q3 gross profit was $0.13 million, a 16.7% margin, versus $0.45 million and 41.1% a year earlier. Nine-month gross profit was $0.68 million, a 26.1% margin, versus $1.21 million and 39.5% in 2015.
- Operating expenses and losses: Q3 operating expenses were $4.58 million and net loss was $5.26 million, versus $3.82 million and $3.56 million in 2015. Nine-month operating expenses were $12.65 million and net loss was $12.97 million, versus $11.47 million and $10.72 million. Nine-month basic and diluted loss per share was $18.36, versus $18.71 in 2015.
- Cash flow: Nine-month operating cash use was $13.59 million, compared with $7.18 million in 2015. Investing cash use was $3.01 million; financing provided $15.57 million. Cash and cash equivalents declined by $1.03 million to $2.32 million.
- Liquidity and debt: At September 30, cash and short-term investments totaled $14.15 million; current assets were $17.96 million and current liabilities $5.21 million. Long-term debt was $9.89 million carrying value ($10.0 million principal), with no current portion. Accumulated deficit was $69.1 million.
Changes, outlook, and risks
- Revenue declined as the company discontinued sales in certain international markets and reduced Middle East volume ahead of transitioning to its current-generation product. Bader accounted for 100% of nine-month 2016 revenue; accounts receivable from Bader was $0.52 million.
- R&D fell year over year, principally because the SMART clinical trial concluded. SG&A rose sharply with hiring, legal and intellectual-property costs, and sales-and-marketing preparation for U.S. commercialization. Q3 cost of revenue also included FDA-approval-related costs and a write-down of obsolete materials.
- The company reported FDA premarket approval in September and anticipated a U.S. commercial launch in early 2017. It expected to build a direct sales force of approximately 20–25 people and expand manufacturing. Management projected that IPO proceeds, existing liquidity, and expected revenue would fund operations through the next two years; this is a company estimate, not a guarantee.
- After quarter-end, the IPO closed October 12, 2016: 5.0 million shares at $15 each, for approximately $67.4 million net proceeds. Preferred stock converted into common stock at closing. This post-period financing materially changed the liquidity picture.
- Debt terms include a $5.0 million additional tranche available through March 7, 2017, variable interest at the greater of prime plus 1.50% or 5.00%, and interest-only payments through March 2018. The loan is secured by substantially all assets other than intellectual property and includes operating restrictions and cash-management requirements.
- Key risks include ongoing losses and cash burn; dependence on one related-party distributor for historical revenue; uncertain U.S. adoption, self-pay demand, and competition; device safety, product-liability and regulatory risks; reliance on single-source suppliers; and facility lease expiry in March 2017. The filing reports no legal proceeding believed likely to have a material adverse effect. Management said disclosure controls were effective as of September 30, 2016.
- No formal financial guidance was provided. Management expected continuing losses and higher costs as it commercialized the product, expanded sales and manufacturing, pursued R&D, and incurred public-company expenses.
Investor verification checklist
- Confirm the intended issuer: the supplied filing is Obalon Therapeutics, not Vyome Holdings.
- Verify the IPO closing date and net proceeds, and assess actual cash runway against management’s two-year estimate.
- Track U.S. launch timing, sales-force buildout, production capacity, and adoption by physicians and patients paying out of pocket.
- Monitor revenue concentration, Bader’s purchases and receivables, and any transition to the current-generation product.
- Review clinical and post-approval safety results, supplier continuity, facility arrangements, and compliance with the loan covenants.